blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4007818

EP4007818 - METHODS AND REAGENTS FOR NUCLEIC ACID SEQUENCING AND ASSOCIATED APPLICATIONS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  06.05.2022
Database last updated on 02.09.2024
FormerThe international publication has been made
Status updated on  05.02.2021
Most recent event   Tooltip10.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Twinstrand Biosciences, Inc.
3131 Elliot Ave., Suite 750
Seattle, WA 98121 / US
[2022/23]
Inventor(s)01 / SALK, Jesse J.
10704 Durland Avenue NE
Seattle, Washington 98125 / US
 [2022/23]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2022/23]
Application number, filing date20848607.601.08.2020
[2022/23]
WO2020US44673
Priority number, dateUS201962881936P01.08.2019         Original published format: US 201962881936 P
[2022/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021022237
Date:04.02.2021
Language:EN
[2021/05]
Type: A1 Application with search report 
No.:EP4007818
Date:08.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 04.02.2021 takes the place of the publication of the European patent application.
[2022/23]
Search report(s)International search report - published on:US04.02.2021
(Supplementary) European search report - dispatched on:EP22.08.2023
ClassificationIPC:C12Q1/6844, C12Q1/6855, C12Q1/686, C12Q1/6869, C12Q1/6874, C12Q1/6876, C12Q1/6827
[2023/38]
CPC:
C12Q1/6827 (EP,IL,US); C12Q1/6869 (EP,IL,US)
C-Set:
C12Q1/6827, C12Q2521/301, C12Q2525/191, C12Q2531/113, C12Q2535/122, C12Q2563/149, C12Q2563/179, C12Q2565/50 (EP);
C12Q1/6869, C12Q2521/301, C12Q2525/191, C12Q2531/113, C12Q2563/149, C12Q2563/179, C12Q2565/50 (EP)
Former IPC [2022/23]C12Q1/6844, C12Q1/6855, C12Q1/686, C12Q1/6869, C12Q1/6874, C12Q1/6876
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/23]
TitleGerman:VERFAHREN UND REAGENZIEN ZUM SEQUENZIEREN VON NUKLEINSÄUREN UND ZUGEHÖRIGE ANWENDUNGEN[2022/23]
English:METHODS AND REAGENTS FOR NUCLEIC ACID SEQUENCING AND ASSOCIATED APPLICATIONS[2022/23]
French:PROCÉDÉS ET RÉACTIFS POUR LE SÉQUENÇAGE D'ACIDES NUCLÉIQUES ET APPLICATIONS ASSOCIÉES[2022/23]
Entry into regional phase01.03.2022National basic fee paid 
01.03.2022Search fee paid 
01.03.2022Designation fee(s) paid 
01.03.2022Examination fee paid 
Examination procedure01.03.2022Examination requested  [2022/23]
18.03.2024Amendment by applicant (claims and/or description)
18.03.2024Date on which the examining division has become responsible
Fees paidRenewal fee
01.03.2022Renewal fee patent year 03
09.08.2023Renewal fee patent year 04
09.08.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US2017211140  (SCHMITT MICHAEL W [US], et al) [X] 1-16 * [0006], claims 1-178 and 180-218 *;
 [X]WO2018175997  (UNIV WASHINGTON [US]) [X] 1-16 * claims 1-55, [0009], [0016], [0031], [0104], [0123], [0149] and Fig. 1 *;
 [XA]  - JESSE J. SALK ET AL, "Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations", NATURE REVIEWS GENETICS, GB, (20180326), vol. 19, no. 5, doi:10.1038/nrg.2017.117, ISSN 1471-0056, pages 269 - 285, XP055681812 [X] 1 * p. 10-11 * [A] 2-16

DOI:   http://dx.doi.org/10.1038/nrg.2017.117
International search[A]WO2012012037  (NEW ENGLAND BIOLABS INC [US], et al) [A] 1-12* entire document *;
 [A]WO2012061832  (ILLUMINA INC [US], et al) [A] 1-12 * entire document *;
 [A]WO2013123442  (HUTCHINSON FRED CANCER RES [US]) [A] 1-12 * entire document *;
 [A]US2013303461  (IAFRATE ANTHONY JOHN [US], et al) [A] 1-12 * entire document *;
 [A]WO2015100427  (GUARDANT HEALTH INC [US]) [A] 1-12 * entire document *;
 [A]US2016208241  (TSAI YU-CHIH [US], et al) [A] 1-12 * entire document *;
 [A]US2016362751  (SHIN GIWON [US], et al) [A] 1-12 * entire document *;
 [A]WO2017100441  (TWINSTRAND BIOSCIENCES INC [US], et al) [A] 1-12 * entire document *;
 [X]WO2018175997  (UNIV WASHINGTON [US]) [X] 1-12 * entire document *;
 [A]WO2018183942  (GRAIL INC [US]) [A] 1-12 * entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.